NC
CLVS

Nexthera Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Nexthera Capital’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-242,600
Closed -$12.8M – 58
2018
Q1 		$12.8M Buy
242,600
+9,400
+4% +$548K 2.11% 16
2017
Q4 		$15.9M Buy
233,200
+198,200
+566% +$13.9M 2.92% 9
2017
Q3 		$2.88M Buy
+35,000
New +$2.77M 0.74% 30

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Nexthera Capital's CLVS Position: Q4 2017 in Review

Nexthera Capital sold out of Clovis Oncology, Inc. (CLVS) in Q4 2017, closing a stake of 184,680 shares — an estimated $12.9M sold.

Nexthera Capital first reported a position in CLVS in Q3 2016 and held it in 2 quarters. The position peaked at $15.2M in Q3 2017. 247 funds tracked by Wall St. Rank hold CLVS as of Q4 2017.

  • Nexthera Capital reported no remaining Clovis Oncology, Inc. position as of Q4 2017 after selling out during the quarter.
  • Nexthera Capital sold 184,680 Clovis Oncology, Inc. shares in Q4 2017, an estimated $12.9M.
  • Nexthera Capital first reported a position in Clovis Oncology, Inc. in Q3 2016 and held it in 2 quarters.
  • Nexthera Capital's Clovis Oncology, Inc. position peaked at $15.2M in Q3 2017.
  • 247 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2017.

Based on Nexthera Capital's 13F filing for Q4 2017, filed 14 Feb 2018.